{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:48:36Z","timestamp":1791431316647,"version":"4.3.3"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.oret.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T21:45:24Z","timestamp":1569620724000},"page":"122-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States"],"prefix":"10.1016","volume":"4","author":[{"given":"Arshad M.","family":"Khanani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Skelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Bezlyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Griner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Rodriguez","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Sagkriotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2019.09.009_bib1","series-title":"The aging eye. Common eye diseases and their management","author":"Galloway","year":"2006"},{"key":"10.1016\/j.oret.2019.09.009_bib2","series-title":"Vision 2020 The Right to Sight. Global Initiative for the elimination of avoidable blindness. Action plan 2006\u20132011","year":"2007"},{"key":"10.1016\/j.oret.2019.09.009_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"2-a Suppl","key":"10.1016\/j.oret.2019.09.009_bib4","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.oret.2019.09.009_bib5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/jamaophthalmol.2013.6636","article-title":"Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36","volume":"132","author":"Chew","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000438969","article-title":"Neovascular age-related macular degeneration","volume":"55","author":"Shao","year":"2016","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamaophthalmol.2014.4252","article-title":"Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study","volume":"133","author":"Gangnon","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib8","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","article-title":"The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes","volume":"121","author":"Zarranz-Ventura","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.09.009_bib9","first-page":"786870","article-title":"Anti-VEGF treatment strategies for wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib10","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.09.009_bib11","series-title":"Lucentis prescribing information","year":"2018"},{"key":"10.1016\/j.oret.2019.09.009_bib12","series-title":"Eylea prescribing information","year":"2018"},{"key":"10.1016\/j.oret.2019.09.009_bib13","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.09.009_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133968","article-title":"Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA","volume":"10","author":"Ferreira","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2019.09.009_bib15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.09.009_bib16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12325-017-0483-1","article-title":"A\u00a0retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom","volume":"34","author":"Johnston","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.oret.2019.09.009_bib17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.09.009_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP)","volume":"25","author":"Andrews","year":"2016","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.oret.2019.09.009_bib19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"12","author":"Vandenbroucke","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.oret.2019.09.009_bib20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2019.09.009_bib21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","article-title":"Novel method for analyzing Snellen visual acuity measurements","volume":"30","author":"Gregori","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.09.009_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","article-title":"Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR","volume":"117","author":"Bressler","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.09.009_bib23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archophthalmol.2011.140","article-title":"Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration","volume":"129","author":"Bressler","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/cxo.12292","article-title":"Distance word acuity, critical print size and driving vision standards","volume":"98","author":"Rae","year":"2015","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.oret.2019.09.009_bib25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/eye.2016.324","article-title":"Neovascular age-related macular degeneration: is it worthwhile treating an eye with poor visual acuity, if the visual acuity of the fellow eye is good?","volume":"31","author":"Rasmussen","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.09.009_bib26","article-title":"Baseline characteristics of the fellow eye in patients with wet age-related macular degeneration: post-hoc analysis of the VIEW Studies","volume":"55","author":"Korobelnik","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2019.09.009_bib27","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/eye.2011.224","article-title":"Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6\/12","volume":"25","author":"Williams","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.09.009_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.09.009_bib29","article-title":"Effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration: Twelve-month results from the final analysis of the real-world LUMINOUS study","author":"Holz","year":"2017","journal-title":"EURETINA"},{"key":"10.1016\/j.oret.2019.09.009_bib30","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","article-title":"Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study","volume":"100","author":"Holz","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib31","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.09.009_bib32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.09.009_bib33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib34","first-page":"81","article-title":"Six-year outcomes in neovascular age-related macular degeneration with ranibizumab","volume":"10","author":"Jacob","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib35","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.09.009_bib36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/eye.2012.225","article-title":"Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?","volume":"27","author":"Ross","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.oret.2019.09.009_bib37","doi-asserted-by":"crossref","first-page":"A561","DOI":"10.1016\/j.jval.2016.09.1245","article-title":"Three year clinical effectiveness of ranibizumab and aflibercept for neovascular age-related macular degeneration: a retrospective cohort study using electronic medical records from the USA","volume":"19","author":"Milnes","year":"2016","journal-title":"Value in Health"},{"key":"10.1016\/j.oret.2019.09.009_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.09.009_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14728214.2014.884559","article-title":"Emerging treatments for wet age-related macular degeneration","volume":"19","author":"Smith","year":"2014","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.oret.2019.09.009_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/tjo.28003","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"10.1016\/j.oret.2019.09.009_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fmed.2018.00125","article-title":"Outcome of 5-year treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF using \u201ctreat and extend\u201d regimen","volume":"5","author":"Jaki Mekjavic","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.oret.2019.09.009_bib42","first-page":"1079","article-title":"Individualized treatment of neovascular age-related macular degeneration: what are patients gaining? Or losing?","volume":"4","author":"Stewart","year":"2015","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.oret.2019.09.009_bib43","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.oret.2019.09.009_bib44","first-page":"464","article-title":"Real-world evidence: promise\u00a0and peril for medical product evaluation","volume":"43","author":"Dhruva","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.oret.2019.09.009_bib45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/eye.2016.269","article-title":"Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA","volume":"31","author":"Nghiem-Buffet","year":"2017","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865301930569X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865301930569X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:27:20Z","timestamp":1762853240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865301930569X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S246865301930569X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2019.09.009","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license ?(<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/?creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}